tetano
Editor, Senior Moderator
Dev Comp Immunol. 2016 Oct 27. pii: S0145-305X(16)30371-8. doi: 10.1016/j.dci.2016.10.010. [Epub ahead of print]
[h=1]Generation and characterization of new monoclonal antibodies against swine origin 2009 influenza A (H1N1) virus and evaluation of their prophylactic and therapeutic efficacy in a mouse model.[/h] Wang SF[SUP]1[/SUP], Tseng SP[SUP]2[/SUP], Loh EW[SUP]3[/SUP], Wang WH[SUP]4[/SUP], Li MC[SUP]5[/SUP], Chen KH[SUP]6[/SUP], Tsai WC[SUP]2[/SUP], Lee YM[SUP]7[/SUP], Chen HY[SUP]8[/SUP], Liu FT[SUP]8[/SUP], Arthur Chen YM[SUP]9[/SUP], Huang JC[SUP]10[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] In 2009, a swine-origin influenza A virus - A(H1N1)pdm09 - emerged and has became a pandemic strain circulating worldwide. The hemagglutinin (HA) of influenza virus is a potential target for the development of anti-viral therapeutic agents. Here, we generated mAbs by immunization of baculovirus-insect expressing trimeric recombinant HA of the A(H1N1)pdm09 strain. Results indicated that the mAbs recognized two novel neutralizing and protective epitopes-"STAS" and "FRSK" which located near Cb and Ca1 antigenic regions respectively and were conserved in almost 2009-2016 influenza H1N1 stains. The mAb 12E11 demonstrated higher protective efficacy than mAb 8B10 in mice challenge assay. Both mAb pretreatments significantly reduced virus titers and pro-inflammatory cytokines in mice lung postinfection (p < 0.01), and showed prophylactic and therapeutic efficacies even 48 h postinfection (p < 0.05). Combination therapy using the mAbs with oseltamivir pre- and post-treatment showed synergistic therapeutic effect in mice model (p < 0.01). Further investigation for clinical application in humans is warranted.
Copyright ? 2016. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Epitope; H1N1; Influenza virus; Monoclonal antibody; Prophylactic; Therapeutic; Trimeric hemagglutinin
PMID: 27984103 DOI: 10.1016/j.dci.2016.10.010
[PubMed - as supplied by publisher]
[h=1]Generation and characterization of new monoclonal antibodies against swine origin 2009 influenza A (H1N1) virus and evaluation of their prophylactic and therapeutic efficacy in a mouse model.[/h] Wang SF[SUP]1[/SUP], Tseng SP[SUP]2[/SUP], Loh EW[SUP]3[/SUP], Wang WH[SUP]4[/SUP], Li MC[SUP]5[/SUP], Chen KH[SUP]6[/SUP], Tsai WC[SUP]2[/SUP], Lee YM[SUP]7[/SUP], Chen HY[SUP]8[/SUP], Liu FT[SUP]8[/SUP], Arthur Chen YM[SUP]9[/SUP], Huang JC[SUP]10[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] In 2009, a swine-origin influenza A virus - A(H1N1)pdm09 - emerged and has became a pandemic strain circulating worldwide. The hemagglutinin (HA) of influenza virus is a potential target for the development of anti-viral therapeutic agents. Here, we generated mAbs by immunization of baculovirus-insect expressing trimeric recombinant HA of the A(H1N1)pdm09 strain. Results indicated that the mAbs recognized two novel neutralizing and protective epitopes-"STAS" and "FRSK" which located near Cb and Ca1 antigenic regions respectively and were conserved in almost 2009-2016 influenza H1N1 stains. The mAb 12E11 demonstrated higher protective efficacy than mAb 8B10 in mice challenge assay. Both mAb pretreatments significantly reduced virus titers and pro-inflammatory cytokines in mice lung postinfection (p < 0.01), and showed prophylactic and therapeutic efficacies even 48 h postinfection (p < 0.05). Combination therapy using the mAbs with oseltamivir pre- and post-treatment showed synergistic therapeutic effect in mice model (p < 0.01). Further investigation for clinical application in humans is warranted.
Copyright ? 2016. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Epitope; H1N1; Influenza virus; Monoclonal antibody; Prophylactic; Therapeutic; Trimeric hemagglutinin
PMID: 27984103 DOI: 10.1016/j.dci.2016.10.010
[PubMed - as supplied by publisher]